Navigation Links
Herceptin Again Proves Mettle Against Breast Cancer
Date:1/28/2010

Improved survival seen when used with chemo for HER2 malignancies, researchers report

THURSDAY, Jan. 28 (HealthDay News) -- High-risk breast cancer patients with HER2-positive tumors benefit from receiving the targeted therapy Herceptin while undergoing chemotherapy, new research shows.

"It's in a European journal [The Lancet], but it's something many of us in the U.S. have already begun to do," said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La. "It just confirms what has really become standard of care in this country, but it's very nice to see it done in a scientific way," he added.

"The reason why Herceptin is so valuable to patients who have locally advanced breast cancer is they have a very bad prognosis," he continued. "The cancers are usually bigger. They may have spread to the lymph nodes in the armpits and they're usually not small enough to be cut out to preserve the breast."

When Brooks sees a patient with locally advanced breast cancer, he treats them first with chemotherapy, to shrink the tumor, along with trastuzumab (Herceptin). Once chemo is completed -- after about six months -- it's easier to operate and remove the tumor. Then the patient is continued on Herceptin for a year, followed by radiation.

The new study, one of the largest looking at Herceptin in this context, was funded by Hoffmann-La Roche, which makes the drug. It appears in the Jan. 30 issue of The Lancet.

Previous research has shown that Herceptin with chemotherapy helped women with both early and metastatic breast cancer live longer.

According to the study authors, from IRCCS Istituto Nazionale de Tumori in Milan, about 22 percent of early breast cancers, 35 percent of locally advanced breast cancers and metastatic tumors, and 40 percent of inflammatory breast cancers overexpress HER2 (human epidermal growth factor receptor-2). These tumors tend to be more aggressive, resulting in shorter survival times.

For this study, 235 women were randomly assigned to receive chemotherapy either with or without one year of Herceptin. In this arm of the trial, the Herceptin was given with chemotherapy (before surgery), then alone.

The second group of patients received chemotherapy before surgery, but no Herceptin.

All participants had either HER2-positive locally advanced breast cancer or inflammatory breast cancer, a rare and deadly form of the disease.

Seventy-one percent of women who received Herceptin were alive without a recurrence at the end of three years, versus 56 percent of women in the control group.

Encouragingly, there were few cardiac problems in the Herceptin group and those that did experience heart problems responded to drugs. Previous studies had shown a much higher rate of heart problems in patients receiving Herceptin.

More information

For more on breast cancer, visit the U.S. National Cancer Institute.



SOURCES: Jay Brooks, M.D., chairman, hematology/oncology, Ochsner Health System, Baton Rouge, La.; Jan. 30, 2010, The Lancet


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Herceptin helps women with multiple chromosomes containing HER2 gene, study finds
2. Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
3. If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer
4. Mathematical modeling predicts response to Herceptin
5. Routine Testing Would Improve Herceptin Use in Breast Cancer
6. Biosimilars of Rituxan, MabThera, Herceptin and Erbitux will Erode $8.2 Billion in U.S. and European Sales in 2018
7. Chemo With Herceptin May Be Best for Some Breast Cancers
8. Mayo Clinic researchers say breast cancer survival improves Herceptin used with chemotherapy
9. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
10. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
11. Despite overeating, morbidly obese mice gain protection against diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing skills ... patients and their families pay tribute to a genetic counselor by nominating him or ... Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome magazine ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
Breaking Medicine Technology: